Novo Nordisk's Subscription Model Aims to Broaden Obesity Drug Market

Novo Nordisk (NYSE: NVO) is rolling out a subscription model for its obesity drug Wegovy, aiming to enhance patient access and expand the market for weight loss treatments. This strategy follows the company's efforts to regain ground in the anti-obesity space after losing some momentum to Eli Lilly (NYSE: LLY) in recent years. The Danish pharmaceutical giant has introduced prescriptions for Wegovy in three, six, or 12-month plans, which patients can access through telehealth platforms. By offering longer subscription terms, Novo Nordisk hopes to reduce out-of-pocket costs for patients and attract a broader user base. The obesity drug market remains underpenetrated, with only 12% of U.S. adults currently using GLP-1 receptor agonists, despite an estimated 40.3% of the population being classified as obese under the standard BMI definition. Researchers suggest that a more accurate measure of obesity prevalence could place the figure closer to 70%, highlighting the vast potential for growth in this sector. Novo Nordisk's initiative could help bridge the gap between the current low adoption rate and the large number of individuals who could benefit from these medications. The company's stock is currently trading at a discount, with a forward price-to-earnings ratio of 11x, compared to the healthcare sector average of 17.3x. This valuation may appeal to investors seeking long-term growth in the pharmaceutical industry. While Eli Lilly is expected to respond to Novo Nordisk's pricing shift, the Danish firm's pipeline of new obesity treatments could provide a competitive edge in the coming years.